Alternative bounded and monotonically decreasing functions do not accurately fit the bias in the naïve SI. by Liron Sheintuch (12078310)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

N1-specific anti-serum decreases replication of A(H1N1)pdm09 in HAE cells. by Anouk Smet (713884)

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Excision of HIF1α decreases viral reactivation from latency in infected splenocytes in vivo. by Darlah M. López-Rodríguez (8098544)

ROC curve and P-R curve (attack traffic proportion = 50%). by Longyan Ran (18452261)

TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin. by Martin Selinger (3195987)

Decreasing fluconazole susceptibility of clinical South African <i>Cryptococcus neoformans</i> isolates over a decade by Serisha D. Naicker (8648370)

ngLVA degradation kinetics. by Nicole A. Grieshaber (11175417)

“…Chloramphenicol treated sample showed a decrease of half max intensity 30 mins after treatment.…”

1466 slows the capsid assembly rate in biochemical Cp149 capsid assembly reactions. by Daniel P. Bradley (10306893)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”